News Sentiment

ACTU sentiment intelligence

Actuate Therapeutics, Inc. Common stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 68 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.44 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 61

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

+19.0% over one week, -30.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Johnson & Johnson stock trades steadily as diversified healthcare earnings and pipeline support long

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 19.0% Price confirming higher
Trend fit Trend inactive -30.4% over four weeks
Fair value -77.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 34
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 61
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 6
www.marketscreener.com 4
TradingKey 4
GlobeNewswire 4
Quiver Quantitative 4
Stocktwits 3
Stock Titan 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 20
Analyst action 6
Regulatory and legal 2
Macro sensitivity 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 68
TradingView Direct company coverage

Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Actuate Therapeutics (ACTU) received a Nasdaq notice on July 15, 2026, indicating its Market Value of Listed Securities fell below the required $50 million minimum for the Nasdaq Global Market. The company has 180 days, until January 11, 2027, to regain compliance by maintaining

Tone
Negative 19/100
Event
Market update
Published
17 Jul 2026 20:10
Source
TradingView
TradingView Direct company coverage

Number of shareholders of Actuate Therapeutics, Inc. – NASDAQ:ACTU

This article provides details on the number of shareholders for Actuate Therapeutics, Inc. (NASDAQ: ACTU). It appears to be a stub or a data point from a financial platform, showing the company's stock market information on Nasdaq. The content primarily consists of navigation and

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:39
Source
TradingView
www.marketscreener.com Direct company coverage

Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000E Index

Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 3000E Index. This news follows several other announcements on June 29th and 28th detailing its removal from various Russell indices, including the Russell 2000, Russell 2500, and Russell Small Cap Compl

Tone
Negative 32/100
Event
Market update
Published
29 Jun 2026 18:09
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2500 Index

Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 2500 Index, as well as the Russell 3000E Index, Russell Small Cap Completeness Index, Russell 3000 Index, Russell 2000 Index, Russell Small Cap Comp Growth Benchmark, and Russell 3000 Growth Benchmark.

Tone
Negative 19/100
Event
Market update
Published
29 Jun 2026 17:40
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000 Index

Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 3000 Index, along with several other Russell indices on June 29, 2026. This news comes as the clinical-stage biopharmaceutical company continues to develop therapies for cancer, particularly with its le

Tone
Negative 28/100
Event
Market update
Published
29 Jun 2026 10:12
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Index

Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 2000 Index. This follows a series of similar removals from other Russell indices, including the Russell 3000E, Small Cap Completeness, 2500, and 3000 indices. The company, a clinical-stage biopharmaceut

Tone
Negative 31/100
Event
Market update
Published
29 Jun 2026 10:02
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Growth Benchmark

Actuate Therapeutics, Inc. (NasdaqGM:ACTU) has been removed from the Russell 3000 Growth Benchmark. This news, published on June 28, 2026, comes as the company continues to develop Elraglusib for various cancer treatments. The stock closed at $1.680, reflecting significant year-t

Tone
Negative 18/100
Event
Market update
Published
28 Jun 2026 21:31
Source
www.marketscreener.com
TradingView Direct company coverage

Price to sales forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU

This article focuses on the "Price to sales forward" metric for Actuate Therapeutics, Inc. (NASDAQ: ACTU). It appears to be a stub or a data point from a financial platform, showing that this specific financial data point was generated by human input over a particular period. The

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU

This article focuses on the "Price to earnings forward" metric for Actuate Therapeutics, Inc. (NASDAQ: ACTU). The content is primarily a placeholder or incomplete financial data page from TradingView, indicating that specific financial figures for this metric are not presented wi

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 03:11
Source
TradingView
TradingView Direct company coverage

ACTU Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Actuate Therapeutics, Inc. (ACTU) stock for 2027, based on analyst opinions. It includes current stock performance, historical highs and lows, market capitalization, and upcoming earnings reports, while also addressing frequen

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 20:10
Source
TradingView
TradingKey Direct company coverage

Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Actuate Therapeutics Inc (ACTU). It notes that relevant financial data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The page also presents current st

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 19:10
Source
TradingKey
TradingKey Direct company coverage

Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Actuate Therapeutics Inc (ACTU), detailing analyst ratings, target prices, and EPS expectations. Four analysts currently rate ACTU as a "Buy" with a significant upside potential of +762.07% to a target price of $17.500. The company's

Tone
Positive 70/100
Event
Earnings
Published
18 Jun 2026 05:40
Source
TradingKey
TradingKey Direct company coverage

Actuate Therapeutics Inc (ACTU) Institutional Confidence

This article from TradingKey provides details on the institutional confidence in Actuate Therapeutics Inc (ACTU). It lists major institutional shareholders including Bios Equity Partners, Kairos Ventures, and Voss Capital, along with their shareholdings and recent changes. The st

Tone
Positive 60/100
Event
Market update
Published
18 Jun 2026 04:40
Source
TradingKey
TradingKey Direct company coverage

Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Actuate Therapeutics Inc (ACTU), detailing various financial and investment risk metrics. It includes data on volatility, maximum drawdown, Sharpe Ratio, and turnover rates over different periods. The report highlights historical perfor

Tone
Neutral 50/100
Event
Macro sensitivity
Published
18 Jun 2026 04:40
Source
TradingKey
TradingView Direct company coverage

Actuate Therapeutics, Inc. Financial Disclosures & SEC Filings

This article provides a compilation of Actuate Therapeutics, Inc.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and press releases. It details the company's financial performance, operational updates, and the critical need for funding to continue operations

Tone
Negative 30/100
Event
Market update
Published
13 Jun 2026 20:08
Source
TradingView
Stock Titan Direct company coverage

Experimental cancer drug elraglusib joins landmark pediatric neuroblastoma trial

Actuate Therapeutics announced that its experimental drug elraglusib has been selected for the European BEACON2 Phase 1/2 clinical trial for high-risk pediatric neuroblastoma. Elraglusib, a GSK-3β inhibitor, will be tested in combination with dinutuximab beta and chemotherapy. Th

Tone
Positive 70/100
Event
Market update
Published
10 Jun 2026 14:12
Source
Stock Titan
Investing.com Canada Direct company coverage

H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion By Investing.com

H.C. Wainwright reiterated a Buy rating and $15.00 price target on Actuate Therapeutics (NASDAQ:ACTU) after the company announced the inclusion of its elraglusib drug candidate in the BEACON2 trial for pediatric neuroblastoma. This trial, sponsored by Cancer Research UK,

Tone
Positive 70/100
Event
Analyst action
Published
10 Jun 2026 11:39
Source
Investing.com Canada
GlobeNewswire Direct company coverage

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

Actuate Therapeutics announced that its drug, elraglusib, will be evaluated in the BEACON2 clinical trial for high-risk pediatric neuroblastoma. This multi-arm, multi-stage Phase 1/2 platform trial will assess elraglusib in combination with dinutuximab beta and chemotherapy. The

Tone
Positive 74/100
Event
Market update
Published
09 Jun 2026 12:09
Source
GlobeNewswire
Quiver Quantitative Direct company coverage

Actuate Therapeutics to Evaluate Elraglusib in BEACON2 Clinical Trial for Relapsed Neuroblastoma in Partnership with Cancer Research UK Clinical Trials Unit

Actuate Therapeutics announced that its investigational drug elraglusib will be evaluated in the BEACON2 trial, a Phase 1/2 clinical study sponsored by Cancer Research UK for relapsed and refractory neuroblastoma in pediatric patients. The trial aims to assess elraglusib in combi

Tone
Positive 62/100
Event
Regulatory and legal
Published
09 Jun 2026 11:52
Source
Quiver Quantitative
Market source Direct company coverage

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

Actuate Therapeutics announced compelling clinical and biomarker data for its investigational drug elraglusib from ASCO poster presentations. The data highlights significant improvements in overall survival for metastatic pancreatic cancer patients with specific gene mutations wh

Tone
Positive 75/100
Event
Regulatory and legal
Published
03 Jun 2026 23:39
Source
Market source
GlobeNewswire Direct company coverage

Actuate Therapeutics Announces ASCO Poster Presentations

Actuate Therapeutics announced two poster presentations at the 2026 ASCO Annual Meeting, detailing compelling clinical and biomarker data for its drug, elraglusib, in treating metastatic pancreatic cancer. The data demonstrated significant improvements in overall survival for pat

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 10:40
Source
GlobeNewswire
Stock Titan Direct company coverage

Study: new drug nearly doubles 1-year survival in pancreatic cancer

Actuate Therapeutics announced promising Phase 2 clinical and biomarker data for its drug elraglusib in first-line metastatic pancreatic cancer at ASCO 2026. The data showed that elraglusib, when combined with chemotherapy regimens like gemcitabine/nab-paclitaxel (GnP) or FOLFIRI

Tone
Positive 70/100
Event
Market update
Published
01 Jun 2026 04:10
Source
Stock Titan